Yes, Suboxone does block kratom’s effects. Buprenorphine, the active opioid component in Suboxone, binds to the same brain receptors as kratom’s alkaloids but with roughly 800 times greater affinity. This means buprenorphine essentially locks onto those receptors and prevents kratom from producing its usual effects, including pain relief and euphoria.
Why Suboxone Overpowers Kratom at the Receptor Level
Kratom’s primary active compounds, mitragynine and 7-hydroxymitragynine, produce opioid-like effects by binding to mu-opioid receptors in the brain. These are the same receptors targeted by morphine, fentanyl, and buprenorphine. The critical difference is how tightly each substance grips those receptors.
Buprenorphine has a binding affinity of about 0.9 nanomolar at the mu-opioid receptor, while mitragynine comes in at roughly 709 nanomolar. In pharmacology, a lower number means a stronger grip. So buprenorphine binds nearly 800 times more tightly than kratom’s main alkaloid. When both substances are present, buprenorphine wins the competition for receptor space and displaces kratom’s compounds. This is why clinicians describe buprenorphine as a “potent, competitive partial agonist”: it latches on firmly and doesn’t let go easily.
Both buprenorphine and kratom’s alkaloids are partial agonists, meaning they activate the receptor less strongly than full opioids like morphine or fentanyl. But because buprenorphine’s binding affinity is so much higher, it effectively crowds out kratom. If you take kratom while on a stable Suboxone dose, you’re unlikely to feel much of anything from it.
How Long the Blocking Effect Lasts
Buprenorphine is often described as “long-lived” compared to kratom alkaloids. In human studies, mitragynine has a terminal half-life of roughly 23 hours, but its receptor binding is far weaker to begin with. Buprenorphine’s combination of high receptor affinity and slow dissociation from the receptor means it occupies those binding sites for an extended period. At standard maintenance doses (typically 8 to 16 mg of the buprenorphine component), the blocking effect persists throughout the day.
This sustained occupancy is what makes Suboxone effective as a maintenance medication. It keeps receptors occupied long enough that using kratom between doses produces little to no additional opioid effect.
Suboxone as a Treatment for Kratom Dependence
Because kratom acts on the same receptors as traditional opioids, clinicians have started treating kratom use disorder with the same approach used for opioid addiction. Multiple published case reports document patients successfully transitioning from heavy kratom use to buprenorphine/naloxone maintenance, then staying abstinent from kratom for months or longer.
In one reported case, a patient who had been using kratom heavily was started on a home induction with buprenorphine/naloxone. He initially experienced cravings, so his dose was increased to 16 mg/4 mg daily. At that dose, he abstained from kratom for more than 10 months. The underlying principle is straightforward: buprenorphine displaces kratom’s alkaloids from the receptors while providing enough partial activation to prevent withdrawal symptoms and reduce cravings.
There are no formal guidelines specifically for kratom use disorder yet, but the clinical approach mirrors standard opioid use disorder treatment. Providers have used buprenorphine and clonidine (for symptom management) as the primary tools.
Precipitated Withdrawal Risk
One concern people have when starting Suboxone is precipitated withdrawal, the sudden onset of intense withdrawal symptoms that can happen when buprenorphine rapidly displaces a full opioid agonist from receptors. This is a well-known risk when transitioning from drugs like heroin or fentanyl to Suboxone.
With kratom, the risk appears lower. In a published case series of patients starting buprenorphine after kratom use, none reported precipitated withdrawal symptoms. Providers in these cases instructed patients to wait 24 hours after their last kratom dose before beginning buprenorphine, which is a standard precaution. The lower risk likely relates to the fact that kratom’s alkaloids are themselves partial agonists with weaker receptor binding, so the displacement by buprenorphine is less dramatic than it would be with a full agonist.
That said, the published evidence is still limited to small case reports and case series. Individual experiences can vary depending on how much kratom you’ve been using, for how long, and what other substances are involved.
Drug Interaction Concerns
Beyond the receptor-level competition, there’s a pharmacokinetic wrinkle worth knowing about. Kratom alkaloids are metabolized by the same liver enzymes (CYP2D6 and CYP3A) that process many common medications. At least one documented case involved kratom precipitating toxic interactions with other drugs through these enzyme pathways. If you’re taking Suboxone alongside other medications, kratom use could complicate how your body processes those drugs, even if Suboxone is blocking kratom’s opioid effects.
The bottom line: at a stable Suboxone dose, kratom is unlikely to produce noticeable opioid effects. Buprenorphine’s dramatically stronger receptor binding simply doesn’t leave room for kratom to work. This same mechanism is what makes Suboxone a viable treatment option for people trying to stop using kratom.